Skip to content

Study · Not a test of the peptide alone · 2024

7 results

PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review.

Yu J, Wang Q, Wang L, Zong D, He X

Medicine1 Aug 2024Cited by 1 (Europe PMC)

PMID39183403 (opens in a new tab)PMCIDPMC11346870 (opens in a new tab)DOI10.1097/md.0000000000039271 (opens in a new tab)PepBankPUB-39183403
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

RationaleTriple-negative breast cancer is characterized by a worse prognosis compared with other breast cancer subtypes, especially in the case of pretreated metastatic triple-negative breast cancer (mTNBC). Because of the limited treatment options and suboptimal response rates, there is a pressing need to explore novel treatment protocols.Patient concernsA 48-year-old female patient diagnosed with mTNBC who had not responded to multiple lines of therapy (including surgery, chemotherapy, and radiotherapy) but demonstrated significant efficacy and abscopal effects after enrolling in our clinical trial.DiagnosesTriple-negative breast cancer with lung metastases.InterventionsThe clinical trial combined stereotactic body radiotherapy, immunotherapy, granulocyte-macrophage colony-stimulating factor, and thymosin alpha-1 to treat previously treated metastatic solid cancers.OutcomesThis combined treatment regimen implemented in this clinical trial yielded the patient's notable efficacy, accompanied by abscopal effects. The target lesion and the 3 observed lesions achieved a partial response according to the RECIST v1.1 criteria. reevaluation scans after 2 cycles of immunotherapy indicated a regression rate of -78.97% for the target lesion and -56.73% for the observed lesions. Hematological indexes were stable, and there was no apparent myelosuppression. Also, the tumor marker CA-199 exhibited a downward trend. During the course of treatment, the patient experienced a grade 2 skin reaction, which improved after receiving antiallergic treatment. No further adverse effects were observed.LessonsThis treatment regimen may offer a promising treatment strategy for patients with mTNBC and other metastatic solid cancers.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneCase report or seriesEfficacy outcome

    In a woman with metastatic triple-negative breast cancer, a regimen of SBRT, PD-1 inhibitor, GM-CSF and thymosin alpha‑1 gave a partial response of the target lesion and 3 observed lesions.

    In plain wordsIn one woman with metastatic breast cancer, a regimen of radiotherapy and three drugs shrank the tumors it was measured on.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePartial response by RECIST v1.1
    Study

    n = 1

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The target lesion and the 3 observed lesions achieved a partial response according to the RECIST v1.1 criteria.
    2 context sentences
    Summary · context
    A 48-year-old female patient diagnosed with mTNBC who had not responded to multiple lines of therapy (including surgery, chemotherapy, and radiotherapy) but demonstrated significant efficacy and abscopal effects after enrolling in our clinical trial.
    Summary · context
    The clinical trial combined stereotactic body radiotherapy, immunotherapy, granulocyte-macrophage colony-stimulating factor, and thymosin alpha-1 to treat previously treated metastatic solid cancers.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneCase report or seriesEfficacy outcome

    In a woman with metastatic triple-negative breast cancer, the combined regimen gave a regression rate of -78.97% for the target lesion after 2 cycles.

    In plain wordsIn one woman with metastatic breast cancer, the combined regimen shrank the main tumor after 2 cycles (regression rate -78.97%).

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseRegression rate of the target lesion
    Study

    n = 1

    Outcome group
    Tumor growth · Cancer

    Measurements

    Regression rate
    −78.97%
    target lesion

    Source sentences

    Summary
    reevaluation scans after 2 cycles of immunotherapy indicated a regression rate of -78.97% for the target lesion and -56.73% for the observed lesions.
    2 context sentences
    Summary · context
    A 48-year-old female patient diagnosed with mTNBC who had not responded to multiple lines of therapy (including surgery, chemotherapy, and radiotherapy) but demonstrated significant efficacy and abscopal effects after enrolling in our clinical trial.
    Summary · context
    The clinical trial combined stereotactic body radiotherapy, immunotherapy, granulocyte-macrophage colony-stimulating factor, and thymosin alpha-1 to treat previously treated metastatic solid cancers.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneCase report or seriesEfficacy outcome

    In a woman with metastatic triple-negative breast cancer, the combined regimen gave a regression rate of -56.73% for the observed lesions after 2 cycles (abscopal effect).

    In plain wordsIn one woman with metastatic breast cancer, the combined regimen shrank the other measured tumors after 2 cycles (regression rate -56.73%).

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseRegression rate of the observed lesions
    Study

    n = 1

    Outcome group
    Tumor growth · Cancer

    Measurements

    Regression rate
    −56.73%
    observed lesions

    Source sentences

    Summary
    reevaluation scans after 2 cycles of immunotherapy indicated a regression rate of -78.97% for the target lesion and -56.73% for the observed lesions.
    2 context sentences
    Summary · context
    A 48-year-old female patient diagnosed with mTNBC who had not responded to multiple lines of therapy (including surgery, chemotherapy, and radiotherapy) but demonstrated significant efficacy and abscopal effects after enrolling in our clinical trial.
    Summary · context
    The clinical trial combined stereotactic body radiotherapy, immunotherapy, granulocyte-macrophage colony-stimulating factor, and thymosin alpha-1 to treat previously treated metastatic solid cancers.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneCase report or seriesSafety outcome

    In a woman with metastatic triple-negative breast cancer given the combined regimen, hematological indexes stayed stable with no apparent myelosuppression.

    In plain wordsIn one woman given the combined regimen, blood counts stayed stable and the bone marrow was not clearly suppressed.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeHematological indexes and myelosuppression
    Study

    n = 1

    Outcome group
    Adverse events · Cancer

    Source sentences

    Summary
    Hematological indexes were stable, and there was no apparent myelosuppression.
    2 context sentences
    Summary · context
    A 48-year-old female patient diagnosed with mTNBC who had not responded to multiple lines of therapy (including surgery, chemotherapy, and radiotherapy) but demonstrated significant efficacy and abscopal effects after enrolling in our clinical trial.
    Summary · context
    The clinical trial combined stereotactic body radiotherapy, immunotherapy, granulocyte-macrophage colony-stimulating factor, and thymosin alpha-1 to treat previously treated metastatic solid cancers.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneCase report or seriesEfficacy outcome

    In a woman with metastatic triple-negative breast cancer given the combined regimen, the tumor marker CA-199 showed a downward trend.

    In plain wordsIn one woman given the combined regimen, the blood tumor marker CA-199 trended down.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTumor marker CA-199
    Study

    n = 1

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Also, the tumor marker CA-199 exhibited a downward trend.
    2 context sentences
    Summary · context
    A 48-year-old female patient diagnosed with mTNBC who had not responded to multiple lines of therapy (including surgery, chemotherapy, and radiotherapy) but demonstrated significant efficacy and abscopal effects after enrolling in our clinical trial.
    Summary · context
    The clinical trial combined stereotactic body radiotherapy, immunotherapy, granulocyte-macrophage colony-stimulating factor, and thymosin alpha-1 to treat previously treated metastatic solid cancers.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneCase report or seriesSafety outcome

    In a woman with metastatic triple-negative breast cancer given the combined regimen, a grade 2 skin reaction occurred and improved with antiallergic treatment.

    In plain wordsIn one woman given the combined regimen, a moderate skin reaction occurred and improved with allergy treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableGrade 2 skin reaction
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    During the course of treatment, the patient experienced a grade 2 skin reaction, which improved after receiving antiallergic treatment.
    2 context sentences
    Summary · context
    A 48-year-old female patient diagnosed with mTNBC who had not responded to multiple lines of therapy (including surgery, chemotherapy, and radiotherapy) but demonstrated significant efficacy and abscopal effects after enrolling in our clinical trial.
    Summary · context
    The clinical trial combined stereotactic body radiotherapy, immunotherapy, granulocyte-macrophage colony-stimulating factor, and thymosin alpha-1 to treat previously treated metastatic solid cancers.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07HumanNot a test of Thymosin alpha-1 aloneCase report or seriesSafety outcome

    In a woman with metastatic triple-negative breast cancer given the combined regimen, no further adverse effects were observed.

    In plain wordsIn one woman given the combined regimen, no other side effects were seen.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeOther adverse effects
    Study

    n = 1

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    No further adverse effects were observed.
    2 context sentences
    Summary · context
    A 48-year-old female patient diagnosed with mTNBC who had not responded to multiple lines of therapy (including surgery, chemotherapy, and radiotherapy) but demonstrated significant efficacy and abscopal effects after enrolling in our clinical trial.
    Summary · context
    The clinical trial combined stereotactic body radiotherapy, immunotherapy, granulocyte-macrophage colony-stimulating factor, and thymosin alpha-1 to treat previously treated metastatic solid cancers.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.